Skip to content
10-K

Annual Report

REGENERX BIOPHARMACEUTICALS, INC.

0001104659-22-040167

← back to feed
Filed
Mar 30, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Mar 18, 2022 143.55M sh
Shares Diluted FY 2021 · Dec 31, 2020 133.36M sh
Operating Cash Flow FY 2021 · Dec 31, 2020 −$1.01M
Cash And Equivalents FY 2021 · Dec 31, 2020 $427.9K
Current Liabilities FY 2021 · Dec 31, 2020 $399.58K
Total Liabilities FY 2021 · Dec 31, 2020 $3.38M
Current Assets FY 2021 · Dec 31, 2020 $477.81K
Total Assets FY 2021 · Dec 31, 2020 $551.79K
Eps Diluted FY 2021 · Dec 31, 2020 −$0.01
Eps Basic FY 2021 · Dec 31, 2020 −$0.01
Sga Expense FY 2021 · Dec 31, 2020 $1.37M
Rd Expense FY 2021 · Dec 31, 2020 $4.92K
Net Income FY 2021 · Dec 31, 2020 −$1.52M
Operating Income FY 2021 · Dec 31, 2020 −$1.29M
Revenue FY 2021 · Dec 31, 2020 $76.76K
Stockholders Equity FY 2021 · Dec 31, 2019 −$2.34M